Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntuitive Inv Regulatory News (IIG)

Share Price Information for Intuitive Inv (IIG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 130.00
Bid: 125.00
Ask: 135.00
Change: 0.00 (0.00%)
Spread: 10.00 (8.00%)
Open: 130.00
High: 130.00
Low: 130.00
Prev. Close: 130.00
IIG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Dispensation from Rule 9 of the Code

20 Apr 2022 11:13

RNS Number : 7647I
Intuitive Investments Group plc
20 April 2022
 

20 April 2022

Intuitive Investments Group Plc

Issue of Second Tranche Consideration Shares

Dispensation from Rule 9 of the Code

On 25 February 2022, the Company announced, amongst other things, that it had acquired Touchless Innovation Limited ("Touchless Innovation"), a provider of disinfection and hygiene services, in exchange for 28,863,636 new Ordinary Shares of 1 penny each in the Company ("Ordinary Shares") (the "Consideration Shares") and £1 million in cash.

The Consideration Shares have been, and are proposed to be, issued in two tranches.

1. The first tranche of 22,589,352 Consideration Shares, were allotted to the selling shareholders of Touchless Innovation on 24 February 2022 of which Stuart White received 19,591,169 Consideration Shares and retained a minority interest of 18.8% in the share capital of Touchless Innovation.

2. The second tranche of 6,274,284 Consideration Shares, ("Second Tranche Consideration Shares"), will now be issued to Stuart White, the Chief Executive Officer of Touchless Innovation.

On the basis that the issued share capital of the Company is 65,790,267 Ordinary Shares (being the issued share capital of the Company as at the date of this announcement) and assuming that:

1. the Second Tranche of the Consideration Shares, of 6,274,284 new Ordinary Shares are issued to Stuart White, increasing the Company's issued share capital to 72,064,551 Ordinary Shares;

2. full use is made by the Company of the share buyback authority under the share buyback resolution passed at the Company's Annual General Meeting of 30 December 2021 ("Share Buyback Resolution"), thereby reducing the issued share capital of the Company by 4,044,182 Ordinary Shares, to 68,020,369 Ordinary Shares; and

3. Stuart White does not dispose of any of his Ordinary Shares pursuant to the Company's exercise of the share buyback authority under the Share Buyback Resolution;

Stuart White's maximum interest in Ordinary Shares would increase to 38.0% of the voting share capital of the Company.

A table is set out below comparing:

1. the current interests of Stuart White in the issued share capital of the Company; and

2. the potential increase in the interests of Stuart White in the issued share capital of the Company following the issue of the Second Tranche of the Consideration Shares; and

3. full implementation of the share buyback authority under the Share Buyback Resolution.

Current position

 

Position following the issue of the Second Tranche of the Consideration Shares

 

Position following full implementation of the share buyback authority

 

No. of Ordinary Shares

% of issued share capital

 

No. of Ordinary Shares

% of issued share capital

 

No. of Ordinary Shares

% of issued share capital

 

19,591,169

29.8%

25,865,453

35.9%

25,865,453

38.0%

Rule 9 of the Code on Takeovers and Mergers (the "Code") and the accelerated Rule 9 Waiver procedure

Under Note 1 on the Notes on Dispensations from Rule 9, the Panel will normally waive the requirement for a general offer to be made in accordance with Rule 9 if, inter alia, those shareholders of the company who are independent of the person who would otherwise be required to make an offer and any person acting in concert with them and do not have any interest in the transaction which may compromise their independence (the "Independent Shareholders") pass an ordinary resolution on a poll at a general meeting (a "Rule 9 Waiver Resolution") approving such a waiver.

Under Note 5(c) on the Notes on Dispensations from Rule 9, the Panel may waive the requirement for a Rule 9 Waiver Resolution to be considered at a general meeting (and for a circular to be prepared in accordance with Section 4 of Appendix 1 to the Code) if Independent Shareholders holding more than 50% of a company's shares capable of being voted on such a resolution confirm to the Panel in writing that they approve such a waiver and would vote in favour of a Rule 9 Waiver Resolution were one to be put to the shareholders of the company at a general meeting.

In accordance with Note 5(c) on the Notes on Dispensations from Rule 9, Independent Shareholders holding shares carrying more than 50% of the voting rights of the Company which would be capable of being cast on a Rule 9 Waiver Resolution have confirmed in writing to the Panel that they approve the proposed waiver and would vote in favour of any resolution to that effect at a general meeting. Accordingly, Stuart White has been granted a dispensation by the Panel from making a mandatory offer under Rule 9 of the Code in relation to the issue of Second Tranche Consideration Shares.

Following the Second Tranche Consideration Shares, Stuart White will have an interest in shares in the Company of not less than 30% of the voting rights of the Company but will not hold shares carrying more than 50% of such voting rights, as set out above.

Under Rule 9 of the Code, Stuart White, or any person acting in concert with Stuart White acquires an interest in any other shares which increases the percentage of shares carrying voting rights in which it is interested, it will normally be required to make a general offer to all the holders of any class of equity share capital or other class of transferable securities carrying voting rights of the Company to acquire the balance of their interests in the Company.

Admission and Total Voting Rights

Application has been made for the admission the 6,274,284 Second Tranche Consideration Shares to trading on AIM and dealings are expected to commence at 8.00 a.m. on or around 26 April 2022.

Immediately following the admission of the Second Tranche Consideration Shares (the "Admission"), the Company's enlarged share capital will comprise 72,064,551 Ordinary Shares.

Each Ordinary Share has one voting right and no Ordinary Shares are held in treasury. Accordingly, immediately following Admission, the total number of voting rights will be 72,064,551. From Admission, this figure may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

For further information, please contact:

 Intuitive Investments Group plc

www.iigplc.com

Julian Baines, Non-Executive Chairman

Robert Naylor, CEO

Via Walbrook PR

 

 

SP Angel Corporate Finance LLP - Nominated Adviser

+44 (0) 20 3470 0470

Jeff Keating / David Hignell / Kasia Brzozowska

 

 

Turner Pope Investments (TPI) Ltd - Broker

+44 (0) 20 3657 0050

Andrew Thacker / James Pope

 

 

 

Walbrook PR Limited - Media & Investor Relations

+44 (0)20 7933 8780 or intuitive@walbrookpr.com

Paul McManus/ Sam Allen

+44 (0) 7980 541 893 / +44 (0) 7502 558 258

 

About Intuitive Investments Group plc

The Company is an investment company seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the chairman of the Investment Committee, David Evans, to seek to generate capital growth over the long term for shareholders.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBGGDSBBDDGDG
Date   Source Headline
8th Apr 20247:00 amRNSIssue and Allotment of Ordinary Shares
22nd Mar 20249:00 amRNSIIG celebrates Sir Nigel Rudd’s award win
21st Mar 20247:00 amRNSIssue and Allotment of Ordinary Shares
7th Mar 20247:00 amRNSHui10 contract win
29th Feb 202410:36 amRNSResult of AGM
28th Feb 20247:00 amRNSIssue of shares
27th Feb 20247:00 amRNSHui10 approved to expand with China Sports Lottery
16th Feb 20247:00 amRNSAppointment of Corporate Broker
6th Feb 202410:45 amRNSPosting of Annual Report and AGM Notice
1st Feb 20242:23 pmRNSTotal Voting Rights
31st Jan 20247:00 amRNSFinancial Results
4th Jan 20242:54 pmRNSIssue of shares
29th Dec 20237:00 amRNSTotal Voting Rights
12th Dec 20233:48 pmRNSIssue of shares
28th Nov 20237:00 amRNSUpdate to the Board of Directors
3rd Nov 20231:36 pmRNSDirector Dealing
1st Nov 202310:41 amRNSHolding(s) in Company
27th Oct 20231:33 pmRNSDirector Dealing
27th Oct 20237:00 amRNSInvestment in Hui10 Inc
31st Aug 20238:25 amRNSTotal Voting Rights
10th Aug 202311:08 amRNSHolding(s) in Company
8th Aug 20238:00 amRNSReadmission - Intuitive Investments Group plc
28th Jul 20233:35 pmRNSGM, Tender Offer & Placing & Directorate Change
13th Jul 20235:02 pmRNSForm 8.3 - Yourgene Health PLC - Correction
11th Jul 202310:47 amRNSNotice of General Meeting - Correction
11th Jul 20237:00 amRNSNotice of General Meeting to approve Proposals
11th Jul 20237:00 amRNSIIG appoints Sir Nigel Rudd as its next Chairman
5th Jul 20233:46 pmRNSFORM 8.3 - Yourgene Health Plc
29th Jun 20237:00 amRNSInterim report for the six months to 31 March 2023
31st May 20237:00 amRNSTotal Voting Rights
24th May 20237:00 amRNSReorganisation and Deferred Consideration
26th Apr 20234:57 pmRNSHolding(s) in Company
17th Jan 202311:19 amRNSResult of AGM and Directorate Change
11th Jan 202310:00 amRNSInvestment in Yourgene Health plc
21st Dec 20227:00 amRNSFinal Results
7th Nov 20222:05 pmRNSSecond Price Monitoring Extn
7th Nov 20222:00 pmRNSPrice Monitoring Extension
5th Aug 20227:00 amRNSInvestment in PneumoWave Limited
26th May 20227:00 amRNSUpdate on Sanondaf
25th May 20227:00 amRNSHalf-year Report
20th Apr 202211:13 amRNSDispensation from Rule 9 of the Code
4th Apr 202211:13 amRNSTotal Voting Rights
8th Mar 20223:39 pmRNSHolding(s) in Company
2nd Mar 20227:00 amRNSSubscription
25th Feb 202212:11 pmRNSInvestment & Appointment of Non-Executive Chair
14th Feb 202212:59 pmRNSChange of Registered Office
14th Feb 20227:00 amRNSInvestment in Ocutec Limited
24th Jan 20228:45 amRNSDirector Dealing
30th Dec 202110:58 amRNSResult of AGM
20th Dec 20217:00 amRNSChange of Registered Office

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.